Access to molecular guided therapy for Langerhans cell histiocytosis patients

J Am Acad Dermatol. 2015 Jul;73(1):e31. doi: 10.1016/j.jaad.2015.03.007.

Authors

Julie Charles¹, Jean-Claude Beani², Mathilde Tardieu², Benoit Busser³

Affiliations

¹ Dermatology Department, Grenoble University Hospital, INSERM U823 Joseph Fourier University, France. Electronic address: [email protected].
² Dermatology Department, Grenoble University Hospital, INSERM U823 Joseph Fourier University, France.
³ Cancer Clinical Laboratory, Grenoble University Hospital, INSERM U823 Joseph Fourier University, France.

PMID: 26089071
DOI: 10.1016/j.jaad.2015.03.007

No abstract available

Publication types

Letter
Kommentar

MeSH terms

Female
Histiocytosis, Langerhans-Cell / drug therapy*
Histiocytosis, Langerhans-Cell / genetics*
Humans
Indoles / therapeutic use*
Proto-Oncogene Proteins B-raf / genetics*
Sulfonamides / therapeutic use*

Substances

Indoles
Sulfonamides
Proto-Oncogene Proteins B-raf